Lonza reports 19% growth in sales in H1
Upgrades 2025 full-year CDMO sales and margin outlook
Upgrades 2025 full-year CDMO sales and margin outlook
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Celecoxib is a nonsteroidal anti-inflammatory drug
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Subscribe To Our Newsletter & Stay Updated